CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that the underwriters have exercised in full their over-allotment option to purchase an additional 900,000 shares of the company’s common stock at the initial public offering price of $10.00 per share granted to them in connection with the company’s initial public offering that priced on May 22nd, 2007.
